SHPH Shuttle Pharmaceuticals Holdings, Inc.
Stock · NasdaqCM · United States · Healthcare · US8256935003
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Shuttle Pharmaceuticals Holdings, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:52. Information, not advice.
Results
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -11.7M | — | -71.60 | +91.3% | -12.5M |
| 2024 | 0 | — | -9.1M | — | -826.00 | +6.4% | -7.3M |
| 2023 | 0 | — | -6.6M | — | -882.50 | +30.0% | -5.6M |
| 2022 | 0 | — | -5M | — | -1,260.00 | — | -2.7M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 28 Feb 2025 | 147.50 | 152.50 | 143.75 | 152.25 | -0.65% | 279 | |
| 27 Feb 2025 | 151.50 | 156.00 | 145.00 | 153.25 | +2.17% | 186 | |
| 26 Feb 2025 | 147.00 | 160.50 | 142.50 | 150.00 | -0.66% | 430 | |
| 25 Feb 2025 | 149.25 | 159.50 | 145.75 | 151.00 | -1.47% | 373 | |
| 24 Feb 2025 | 150.00 | 169.00 | 145.25 | 153.25 | -0.65% | 255 | |
| 21 Feb 2025 | 152.50 | 172.50 | 147.25 | 154.25 | +3.70% | 413 | |
| 20 Feb 2025 | 153.75 | 159.00 | 148.75 | 148.75 | -6.74% | 327 | |
| 19 Feb 2025 | 165.50 | 174.75 | 155.00 | 159.50 | -6.18% | 362 | |
| 18 Feb 2025 | 172.50 | 174.75 | 164.00 | 170.00 | -2.86% | 264 | |
| 14 Feb 2025 | 170.00 | 177.00 | 170.00 | 175.00 | +1.30% | 312 | |
| 13 Feb 2025 | 175.75 | 177.00 | 170.00 | 172.75 | +0.14% | 152 | |
| 12 Feb 2025 | 167.75 | 177.50 | 167.75 | 172.50 | +2.99% | 232 | |
| 11 Feb 2025 | 166.50 | 177.75 | 164.75 | 167.50 | -4.83% | 292 | |
| 10 Feb 2025 | 189.50 | 197.50 | 167.50 | 176.00 | -3.83% | 216 | |
| 07 Feb 2025 | 171.25 | 190.00 | 171.25 | 183.00 | +6.86% | 79 | |
| 06 Feb 2025 | 175.00 | 182.50 | 171.25 | 171.25 | +2.24% | 48 | |
| 05 Feb 2025 | 175.00 | 175.00 | 158.00 | 167.50 | -5.63% | 131 | |
| 04 Feb 2025 | 180.00 | 197.50 | 175.00 | 177.50 | -1.39% | 45 | |
| 03 Feb 2025 | 185.00 | 185.00 | 167.50 | 180.00 | -4.38% | 101 | |
| 31 Jan 2025 | 192.75 | 199.50 | 187.50 | 188.25 | -4.08% | 62 | |
| 30 Jan 2025 | 184.50 | 207.00 | 183.75 | 196.25 | +4.53% | 73 | |
| 29 Jan 2025 | 195.75 | 205.50 | 182.50 | 187.75 | -4.09% | 140 | |
| 28 Jan 2025 | 222.50 | 222.50 | 191.00 | 195.75 | -7.88% | 174 | |
| 27 Jan 2025 | 227.50 | 227.50 | 207.50 | 212.50 | -4.17% | 143 | |
| 24 Jan 2025 | 230.00 | 231.25 | 215.00 | 221.75 | -3.59% | 197 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
Key data
- Previous close
- 5.04 USD
- Market cap
- 26.6M
- Exchange
- NasdaqCM
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 3.5 / 10 No figures for this part: it counts as a cautious 35%. | — |
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -168.3× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 60% of the figures (grade C). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Price / book | 0.29× | Good | 3.81× |
| EV / EBITDA | -2.76× | Weak | 12.63× |
| Free cash flow yield | -10.7% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 58.6% |
| Operating margin | 0% | Weak | 7.8% |
| Net margin | 0% | Weak | 2.8% |
| Return on equity | -90.1% | Weak | 5.7% |
| Return on assets | -49.5% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.01× | Good | 0.48× |
| Interest cover | -168.25× | Weak | 2.76× |
| Current ratio | 0.11× | Weak | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow SHPH and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.